Verastem Oncology terminated an early‑stage trial of its MEK inhibitor Avmapki in lung cancer and said it will refocus resources on a KRAS‑targeting program. Separately, Genmab ended development of the bispecific acasunlimab—an asset BioNTech had previously abandoned—removing it from the company’s lung cancer pipeline. Both moves illustrate active portfolio pruning following underwhelming efficacy signals and emphasize strategic reallocations toward programs with higher perceived probability of success.